Travere Therapeutics, Inc.
TVTX
Updated: 23/09/2026, 23:27:42
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
No summaries found.
- Share price
- $59.83
- Market cap
- $5.56B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Eric Dube
- Employees
- 497
- IPO date
- 08/11/2012
- Beta
- 1.059
- Last dividend
- $0.00
- Day range
- $58.32 – $60.89
- 52-week range
- $22.06 – $68.73
- 1-day performance
- -0.75%
- 1-year performance
- 171.28%
- Current drawdown (1Y)
- -12.95%
- CIK
- 0001438533
- CUSIP
- 89422G107
- ISIN
- US89422G1076
- Created
- 07/12/2025, 14:49:55
- Last update
- 23/09/2026, 23:27:42
Track Travere Therapeutics, Inc. with an AI analyst
See which prediction-market events move TVTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Travere Therapeutics (NASDAQ: TVTX) Gains Analyst Confidence Amidst New Kidney Disease Drug Partnership
Market Data • Market Data • 02/06/2026, 19:10:49
Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript
Seeking Alpha • STOCK • 02/06/2026, 13:32:14
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 21:30:45
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Business Wire • STOCK • 07/05/2026, 00:28:00
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 09:21:15
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research • STOCK • 04/05/2026, 21:01:13
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research • STOCK • 04/05/2026, 20:10:20
Travere Therapeutics Reports First Quarter 2026 Financial Results
Business Wire • STOCK • 04/05/2026, 18:01:00
Travere Therapeutics to Report First Quarter 2026 Financial Results
Business Wire • STOCK • 27/04/2026, 18:30:00
Travere Therapeutics: Still Undervalued Post FSGS Approval
Seeking Alpha • STOCK • 21/04/2026, 17:40:43
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval
Seeking Alpha • STOCK • 15/04/2026, 17:21:56
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
Zacks Investment Research • STOCK • 15/04/2026, 13:41:14